# Creative Medical Technology Holdings, Inc

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/en/companies/Creative Medical Technology Holdings, Inc).

## Overview

Creative Medical Technology Holdings, Inc. is a commercial-stage biotechnology company built around a portfolio of regenerative medicine and cell-therapy concepts. The company traces its roots to intellectual property originally acquired for erectile dysfunction treatment and has since expanded into immune-cell reprogramming and stem-cell-based programs across urology, endocrinology, neurology, orthopedics, and other disease areas. Its operating model is still largely development-focused, with research, clinical trials, and IP monetization driving the business rather than meaningful product sales. The company also uses subsidiaries such as ImmCelz, StemSpine, and AlloCelz to organize its therapeutic platforms and development programs.

## Products & services

• ImmCelz™ platform (CELZ-100) immune-cell reprogramming therapy
• CELZ-201 chronic lower back pain clinical program
• CELZ-201 CREATE-1 Type II diabetes program
• Erectile dysfunction-related IP and therapeutic concepts
• Stem-cell-based regenerative medicine programs
• Preclinical and clinical development of novel biologics

- **Cell therapy platforms** (40%) — Autologous and reprogrammed-cell therapies developed under the ImmCelz platform and related programs.
- **Clinical-stage therapeutic programs** (30%) — Human trials and translational programs such as CELZ-201 for pain and metabolic disease.
- **Intellectual property and licensing** (20%) — Patent-backed assets and disease-specific IP originally centered on erectile dysfunction and expanded indications.
- **Early commercial products and services** (10%) — Small-scale revenue-generating activities and related offerings that have not yet become a core business.

- ImmCelz™ platform (CELZ-100) immune-cell reprogramming therapy
- CELZ-201 chronic lower back pain clinical program
- CELZ-201 CREATE-1 Type II diabetes program
- Erectile dysfunction-related IP and therapeutic concepts
- Stem-cell-based regenerative medicine programs
- Preclinical and clinical development of novel biologics

## Customers

The company’s direct customers are limited because most of its programs are still in development, so the main economic counterparties are clinical trial participants, research collaborators, and industry partners rather than large commercial buyers. In the near term, value is created for physicians, investigators, and partner organizations that support trials in pain, diabetes, urology, and other regenerative medicine indications. If programs advance successfully, future customers would likely include hospitals, specialty clinics, and healthcare providers using approved therapies. The company also depends on investors and capital markets to fund development, which is a critical part of the business model for an early commercial biotechnology company.

- **Clinical trial participants** (primary) — Patients enrolled in studies for chronic lower back pain, diabetes, and other indications to generate safety and efficacy data.
- **Research and industry partners** (primary) — Collaborators that help advance preclinical work, trial execution, and translational development of cell-based therapies.
- **Healthcare providers** (emerging) — Potential future buyers of approved regenerative or biologic therapies if programs reach commercialization.
- **Capital markets investors** (primary) — Equity investors and warrant holders that provide funding for R&D, public-company costs, and clinical advancement.

- Clinical trial participants enrolled in CELZ-201 and related studies
- Physicians and investigators running translational and safety studies
- Research and industry partners supporting cell-therapy development
- Future hospitals and specialty clinics if therapies are approved
- Investors and capital providers funding ongoing R&D and operations

## Geography

The company is headquartered in Phoenix, Arizona, and its reported operations are primarily U.S.-based. The available filings do not disclose a meaningful country revenue split, which is consistent with a development-stage biotechnology company that has not built a broad commercial footprint. Its clinical and research activities appear centered on U.S. programs and U.S. capital markets access. Geography matters mainly through regulatory oversight, clinical trial execution, and the concentration of operating costs in the United States.

- Headquartered in Phoenix, Arizona
- Operations and clinical development are primarily in the United States
- No country-level revenue concentration was disclosed in the excerpts
- U.S. regulatory and clinical-trial execution are central to the business
- Capital raising is tied to U.S. public markets and investor access

## Strategy

The company’s strategy is to advance its regenerative medicine pipeline through clinical data generation, starting with programs such as CELZ-201 in chronic lower back pain and related indications. Management is also broadening the platform beyond the original erectile dysfunction IP into immune-cell reprogramming and stem-cell-based therapies across multiple disease areas. Near-term execution depends on completing cohorts, analyzing safety and efficacy data, and using those results to guide regulatory and development plans. Because the business is still pre-scale, capital raising and disciplined allocation of R&D spending are central to maintaining momentum.

- **Advance clinical cohorts and generate usable efficacy/safety data** (short-term) — Clinical data is the main value driver for a biotechnology company with limited commercial revenue.
- **Broaden the platform across multiple therapeutic indications** (medium-term) — Diversification across pain, diabetes, urology, neurology, and orthopedics reduces dependence on any single program.
- **Secure financing to support R&D and public-company costs** (short-term) — The company is cash-consuming and relies on external capital to continue development.

- Advance CELZ-201 and other clinical programs through cohort data and safety review
- Use trial results to shape future regulatory and development plans
- Expand beyond original ED-related IP into broader regenerative medicine indications
- Develop the ImmCelz, StemSpine, and AlloCelz platforms
- Fund operations through equity and warrant-based financing
- Prioritize research spending on programs with the clearest translational potential

## Risks

The company faces the classic risks of an early-stage biotechnology developer: clinical failure, regulatory delays, and uncertainty around whether early safety signals will translate into durable efficacy. Its programs are still in development, so the business depends on successful trial execution and the ability to raise capital before meaningful product revenue exists. The recent financing activity shows ongoing dilution and warrant-related complexity, which can affect shareholder returns and capital structure. More broadly, biotechnology companies are exposed to scientific, reimbursement, intellectual property, and public-market financing risks, all of which can materially affect valuation and operating continuity.

- **Clinical development failure** [critical] — The company’s value depends on translating early-stage data into successful human trial outcomes and eventual approvals.
- **Capital dilution and financing dependence** [high] — Operations consume cash and the company has relied on warrant exercises and equity-linked financing to fund development.
- **Regulatory and trial-timing uncertainty** [high] — Clinical and regulatory plans depend on cohort data, safety reviews, and agency feedback that can change timelines materially.
- **Intellectual property dependence** [medium] — The company’s origin and differentiation are tied to patents and related IP, which must remain enforceable and relevant.

- Clinical trial risk if CELZ-201 or other programs fail to show efficacy or safety
- Regulatory risk because approvals depend on data quality and agency feedback
- Financing and dilution risk due to recurring equity and warrant issuance
- Commercialization risk because the company has limited product revenue today
- IP and patent risk if core therapeutic claims are challenged or expire
- Execution risk from dependence on partners, trial timing, and research spending
- Biotech sector risk from reimbursement, competition, and capital market volatility

## Accounting

The company’s reported numbers are heavily influenced by development-stage accounting rather than operating scale, so R&D timing and public-company expenses are key analytical items. Revenue is minimal and volatile, which makes quarter-to-quarter comparisons less informative than clinical milestones and cash burn. The March 2025 warrant inducement transaction created financing proceeds and also required equity accounting judgments, including the treatment of the inducement warrants and the expected deemed dividend. Investors should also watch estimates around fair value, stock-based or warrant-related instruments, and the capitalization versus expensing of development activities, because these choices can materially affect reported losses and equity balances.

- **Warrant inducement and equity accounting** — Can materially change equity balances and reported financing-related items
- **R&D expense timing** — Affects comparability of quarterly results and cash burn analysis
- **Fair value measurement of equity-linked instruments** — Can create non-cash charges or equity adjustments

- Revenue is minimal, so reported results are dominated by R&D and G&A expenses
- Quarterly revenue and cost of goods sold are small and can swing materially
- Warrant inducement accounting affects additional paid-in capital and equity presentation
- Fair value estimates for warrants and other equity instruments require judgment
- R&D spending timing affects operating loss and cash burn comparisons
- Public-company and marketing costs can move materially quarter to quarter

---

*Last updated: 2026-08-11T04:46:27.102760+00:00*